[6-K] Enlivex Therapeutics Ltd. Current Report (Foreign Issuer)
Enlivex Therapeutics Ltd. filed a Form 6-K to report its Annual General Meeting of Shareholders is scheduled for November 10, 2025 at 7:00 p.m. Israel time at the company's offices, 14 Einstein Street, Nes Ziona, Israel. The report states that the meeting notice, proxy statement and a form of proxy card are attached as Exhibit 99.1 and Exhibit 99.2 and are incorporated by reference into the report. The filing is signed by CEO Oren Hershkovitz.
Enlivex Therapeutics Ltd. ha presentato un modulo 6-K per comunicare che l'Assemblea Generale Annuale degli azionisti è prevista per 10 novembre 2025 alle ore 19:00 ora di Israele presso gli uffici della società, 14 Einstein Street, Nes Ziona, Israele. Il rapporto indica che l'avviso di riunione, la dichiarazione di procure e un modulo di scheda di procura sono allegati come Exhibit 99.1 e Exhibit 99.2 e sono incorporati nel rapporto per riferimento. La registrazione è firmata dal CEO Oren Hershkovitz.
Enlivex Therapeutics Ltd. presentó un Formulario 6-K para informar que su Asamblea General Anual de Accionistas está programada para 10 de noviembre de 2025 a las 19:00 hora de Israel en las oficinas de la empresa, 14 Einstein Street, Nes Ziona, Israel. El informe indica que el aviso de la reunión, la declaración de poder y un formulario de tarjeta de poder están adjuntos como Exhibit 99.1 y Exhibit 99.2 y se incorporan por referencia al informe. La presentación está firmada por el CEO Oren Hershkovitz.
Enlivex Therapeutics Ltd.는 주주 총회가 2025년 11월 10일 오후 7시(이스라엘 시간)에 회사 사무소인 14 Einstein Street, Nes Ziona, Israel에서 열릴 예정임을 알리기 위해 Form 6-K를 제출했습니다. 보고서에는 회의 공지, 대리인 진술서 및 대리인 표 양식이 Exhibit 99.1 및 Exhibit 99.2로 첨부되어 있으며 보고서에 참조로 포함되어 있습니다. 이 제출서는 CEO Oren Hershkovitz의 서명이 있습니다.
Enlivex Therapeutics Ltd. a déposé un formulaire 6-K pour annoncer que son Assemblée générale annuelle des actionnaires est prévue le 10 novembre 2025 à 19h00, heure d’Israël au siège de la société, 14, rue Einstein, Nes Ziona, Israël. Le rapport indique que l’avis de la réunion, la déclaration de procuration et un formulaire de carte de procuration sont joints en tant que Exhibit 99.1 et Exhibit 99.2 et sont incorporés par référence dans le rapport. Le document est signé par le PDG Oren Hershkovitz.
Enlivex Therapeutics Ltd. hat ein Form 6-K eingereicht, um mitzuteilen, dass die Hauptversammlung der Aktionäre am 10. November 2025, um 19:00 Uhr israelischer Zeit in den Geschäftsräumen des Unternehmens, 14 Einstein Street, Nes Ziona, Israel, stattfinden wird. Der Bericht besagt, dass die Sitzungsankündigung, die Vollmachtsbelehrung und ein Vollmachtsformular als Exhibit 99.1 bzw. Exhibit 99.2 beigefügt sind und in den Bericht Bezug genommen/integriert werden. Die Einreichung wurde vom CEO Oren Hershkovitz unterzeichnet.
Enlivex Therapeutics Ltd. قدمت نموذج 6-K للإبلاغ بأن اجتماع الجمعية العامة السنوية للمساهمين مقرر في 10 نوفمبر 2025 الساعة 7:00 مساءً بتوقيت إسرائيل في مكاتب الشركة، 14 Einstein Street, Nes Ziona, إسرائيل. يذكر التقرير أن جلسة الاجتماع، وإيضاح التوكيل ونموذج بطاقة التوكيل مُرفقة كـ Exhibit 99.1 و Exhibit 99.2 ومُدرجة كمرجع في التقرير. لقد وقعت الإيداع من قبل المدير التنفيذي Oren Hershkovitz.
Enlivex Therapeutics Ltd. 已提交 Form 6-K，宣布其年度股东大会定于2025年11月10日19:00（以色列时间）在公司办公室举行，地址为以色列 Nes Ziona 的 Einstein Street 14 号。报告指出，会议通知、代理声明及一份代理委托书表格作为Exhibit 99.1与Exhibit 99.2附在报告中并被引为参考。该文件由CEO Oren Hershkovitz签署。
- Annual General Meeting scheduled for shareholders on November 10, 2025, providing clear logistics for participation
- Proxy materials attached as Exhibit 99.1 and Exhibit 99.2, enabling shareholders to review and vote
- None.
Insights
TL;DR: Routine annual meeting notice with proxy materials attached; no substantive governance changes disclosed.
The filing provides a standard notification of the company's Annual General Meeting and attaches the meeting notice, proxy statement and proxy card as exhibits. There is no disclosure in this Form 6-K of proposed board changes, shareholder proposals, executive appointments or voting items themselves; those details would appear in the attached proxy statement. From a governance perspective this is a routine procedural filing that informs shareholders of logistics and provides the formal proxy materials for voting.
TL;DR: Administrative disclosure of meeting date and proxy materials; no financial or operational impacts reported.
The report confirms the date, time and location of the Annual General Meeting and states that the notice and proxy materials are attached as exhibits. The Form 6-K does not include financial results, material transactions or forward-looking information. For investors, the filing signals that voting materials are available, but does not present new information that would affect valuation or near-term financial analysis.
Enlivex Therapeutics Ltd. ha presentato un modulo 6-K per comunicare che l'Assemblea Generale Annuale degli azionisti è prevista per 10 novembre 2025 alle ore 19:00 ora di Israele presso gli uffici della società, 14 Einstein Street, Nes Ziona, Israele. Il rapporto indica che l'avviso di riunione, la dichiarazione di procure e un modulo di scheda di procura sono allegati come Exhibit 99.1 e Exhibit 99.2 e sono incorporati nel rapporto per riferimento. La registrazione è firmata dal CEO Oren Hershkovitz.
Enlivex Therapeutics Ltd. presentó un Formulario 6-K para informar que su Asamblea General Anual de Accionistas está programada para 10 de noviembre de 2025 a las 19:00 hora de Israel en las oficinas de la empresa, 14 Einstein Street, Nes Ziona, Israel. El informe indica que el aviso de la reunión, la declaración de poder y un formulario de tarjeta de poder están adjuntos como Exhibit 99.1 y Exhibit 99.2 y se incorporan por referencia al informe. La presentación está firmada por el CEO Oren Hershkovitz.
Enlivex Therapeutics Ltd.는 주주 총회가 2025년 11월 10일 오후 7시(이스라엘 시간)에 회사 사무소인 14 Einstein Street, Nes Ziona, Israel에서 열릴 예정임을 알리기 위해 Form 6-K를 제출했습니다. 보고서에는 회의 공지, 대리인 진술서 및 대리인 표 양식이 Exhibit 99.1 및 Exhibit 99.2로 첨부되어 있으며 보고서에 참조로 포함되어 있습니다. 이 제출서는 CEO Oren Hershkovitz의 서명이 있습니다.
Enlivex Therapeutics Ltd. a déposé un formulaire 6-K pour annoncer que son Assemblée générale annuelle des actionnaires est prévue le 10 novembre 2025 à 19h00, heure d’Israël au siège de la société, 14, rue Einstein, Nes Ziona, Israël. Le rapport indique que l’avis de la réunion, la déclaration de procuration et un formulaire de carte de procuration sont joints en tant que Exhibit 99.1 et Exhibit 99.2 et sont incorporés par référence dans le rapport. Le document est signé par le PDG Oren Hershkovitz.
Enlivex Therapeutics Ltd. hat ein Form 6-K eingereicht, um mitzuteilen, dass die Hauptversammlung der Aktionäre am 10. November 2025, um 19:00 Uhr israelischer Zeit in den Geschäftsräumen des Unternehmens, 14 Einstein Street, Nes Ziona, Israel, stattfinden wird. Der Bericht besagt, dass die Sitzungsankündigung, die Vollmachtsbelehrung und ein Vollmachtsformular als Exhibit 99.1 bzw. Exhibit 99.2 beigefügt sind und in den Bericht Bezug genommen/integriert werden. Die Einreichung wurde vom CEO Oren Hershkovitz unterzeichnet.
FAQ
When is Enlivex (ENLV) holding its 2025 Annual General Meeting?
Where will Enlivex's 2025 Annual General Meeting be held?
Are the proxy materials for Enlivex's meeting available?
Who signed the Form 6-K for Enlivex?
Does the Form 6-K disclose any board changes or material transactions?
